Imatinib was obtained from Novartis and dissolved in the drinking water at 600 mg/liter. For in vivo DC expansion, Flt3L (30 µg in 100 µl PBS; generously provided by Celldex) or control PBS was injected i.p. (nine daily injections). At the indicated time points, the following were administered i.p.: high molecular weight poly I:C (50 µg in 100 µl; InvivoGen) or control PBS; 250 µg anti-CD8 (2.43; Bio X Cell) or rat IgG2b (LTF-2); 1 mg anti–GM-CSF (MP1-22E9; Bio X Cell) or rat IgG2a (2A3); 100 µg anti-IL-1β (B122) or Armenian Hamster IgG (BE0091); or 500 µg loading dose and 250 µg maintenance dose anti-γδTCR (UC7-13D5) or Armenian Hamster IgG (BE0091).
Armenian hamster igg
Manufactured by BioXCell
Sourced in Lebanon
Armenian Hamster IgG is a laboratory reagent that consists of immunoglobulin G (IgG) antibodies derived from Armenian hamsters. IgG is the most abundant type of antibody found in the blood and plays a critical role in the adaptive immune response. The exact applications and intended use of Armenian Hamster IgG are not provided.
Automatically generated - may contain errors
Lab products found in correlation
Rat igg1, by BioXCell (3 mentions)
Anti mouse ifn γ, by BioXCell (2 mentions)
Anti mouse cd11c, by BioXCell (2 mentions)
Anti mouse cd8, by BioXCell (2 mentions)
Anti mouse cd25, by BioXCell (2 mentions)
Clone gk1, by BioXCell (2 mentions)
Rat igg2a, by BioXCell (2 mentions)
Anti il 1β clone b122, by BioXCell (2 mentions)
Anti cd40l mab mr1, by BioXCell (2 mentions)
Anti tnfr2 mabs, by BioXCell (2 mentions)
High molecular weight poly 1 c, by InvivoGen (1 mentions)
Rat igg2b, by BioXCell (1 mentions)
Anti il 1β, by BioXCell (1 mentions)
Anti cd8 2.43, by BioXCell (1 mentions)
Imatinib, by Novartis (1 mentions)
Anti igf 1 ab, by R&D Systems (1 mentions)
Anti ifn γ ab clone xmg1, by BioXCell (1 mentions)
Mouse igg1, by BioXCell (1 mentions)
C57bl 6j mice, by Jackson ImmunoResearch (1 mentions)
Pc 61, by BioXCell (1 mentions)
25 protocols using armenian hamster igg
1
Imatinib and Flt3L-induced DC Expansion
2
Modulating Wound Healing in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Mouse model of Vγ1D was implemented by intraperitoneal injection of 200 μg anti-Vγ1 Ab (clone 2.11; BioXcell, USA) 3 days before wound excision. Vγ4D was generated by anti-Vγ4 Ab (clone UC3-10A6; BioXcell, USA). Control mice were intraperitoneally administrated isotype control (armenian hamster IgG) (BioXcell, USA). Neutralization mouse models were conducted by injecting subcutaneously into wound margin 0, 1, and 2 days following excision with 20 μg/wound of anti-IGF-1 Ab (R&D Systems, Minneapolis, MN, USA), anti-IL-17A Ab (clone 17F3; BioXcell, USA), anti-IFN-γ Ab (clone XMG1.2; BioXcell, USA), anti-IL-1β Ab (clone B122; BioXcell, USA), anti-IL-23 Ab (clone BE0051; BioXcell, USA), anti-CCL20 Ab (clone 114906; R&D Systems, USA), respectively. IL-17A neutralization of low and high doses was performed by 2 and 200 μg/wound of anti-IL-17A Ab, respectively. Isotype control mice received equivalent doses of isotype Abs subcutaneously. Isotype control Abs of IGF-1, IL-17A, IL-1β, IL-23, CCL20 are poly goat IgG, mouse IgG1, armenian hamster IgG, rat IgG2, and rat IgG1 (BioXcell), respectively. Mouse models of recombinant cytokine addition were generated by subcutaneously injecting rIGF-1/rIL-17A/rIL-1β/rIL-23 (R&D Systems, Minneapolis, MN, USA) with the doses of 2, 20, 200 ng/wound, respectively, in the wound margin. Control mice were administrated with sterile PBS.
3
Syngeneic Tumor Models and Immunotherapy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Animals were housed in a specific pathogen-free facility accredited by Association for Assessment and Accreditation of Laboratory Animal Care, and experiments were performed in accordance with Columbia University’s Institutional Animal Care and Use Committee. C57BL/6J mice (Jackson Laboratories) aged 8–12 weeks were used for tumor challenges with B16F10 melanoma expressing SIINFEKL epitope of chicken ovalbumin fused to GFP (provided by Andrea Schietinger, MSKCC) or CMT167 Kras mutant lung carcinoma cells (Sigma-Aldrich), as described.13 (link) Tumor cells (2.5 × 106) were inoculated subcutaneously in the right flank. On d10 (B16-OVA) or d14 (CMT16), draining lymph nodes and tumors were obtained from euthanized mice. For some experiments, mice were randomized to i.p. treatment every three days with isotype control (Armenian Hamster IgG; BioXcell), anti–PD-1 (200 μg [female]; 250 μg [male]) (J43 clone; BioXcell), or combination of anti-PD-1 and anti-LAG-3 (200 μg [female]; 250 μg [male]) (C9B7W clone; BioXcell). CMT167 mice were treated on days 4, 7, 10, and 13. B16-OVA mice were treated on days 3, 6, and 9.
4
Treg Cell Ablation and Depletion Protocol
5
Targeting TNFR1 and TNFR2 in JAK2 Mutant Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For αTNFR1 and αTNFR2 therapy, JAK2+/VF mice were treated for 3 weeks. huTNFR1ecd × JAK2+/VF mice received anti-human TNFR1 antibody H398 (20 mg/kg body weight intraperitoneally per injection38,46 (link)) three times a week. Anti-murine TNFR2 TR75-54.7 antibody was given to JAK2+/VF mice (5 mg/kg body weight intraperitoneally per injection; Bio X Cell, Lebanon, NH) twice a week over 3 weeks.46,47 (link) Control mice received corresponding immunoglobulin G (IgG) isotype controls (αTNFR1: Mouse IgG2a clone C1.18.4; αTNFR2: Armenian Hamster IgG; both from Bio X Cell).
6
Anti-CD40L and BAFF Depletion in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
To block ongoing GC responses, immunized mice were injected i.p. on 3 alternate d with 300 µg anti-CD40L (MR-1; BioXCell). To induce Cre recombinase activity, 2 mg of tamoxifen (20 mg/ml in corn oil; Sigma Aldrich) was administered i.p. daily for 5 d. BAFF depletion in mice was achieved by two i.p. injections of 100 µg anti-BAFF (10F4; GSK) or, as a control, with Armenian hamster IgG (BioXCell).
7
Oxazolone-Induced Delayed-Type Hypersensitivity
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Oxazolone (Sigma) solutions were prepared fresh in ethanol for each experiment. For sensitisation, 150 μl of 3% Oxazolone was applied to the shaven abdominal skin of anaesthetised 5‐ to 10‐week‐old mice. Five days later, left and right ear thickness were measured, and the elicitation phase started by the application of 20 μl of a 1% Oxazolone solution to one ear, or 20 μl of vehicle (100% ethanol) to the contralateral ear. Twenty‐four to 96 h later, ear thickness was measured using a digital micrometer (Mitutoyo). In anti‐OX40 experiments, 0.5 mg of anti‐OX40 (OX86, BioXCell) or rat IgG1 (MAC221, kind gift from Prof. Anne Cooke) was injected i.p. on day of challenge and 48 h later. For anti‐TNFRII experiments, 0.5 mg of anti‐TNFRII (TR75‐54.7 BioXCell) or Armenian hamster IgG (BioXCell) was injected intra‐peritoneally (i.p). on day of challenge.
8
Treg Cell Ablation and Depletion Protocols
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For Treg cell ablation studies, DT (Sigma-Aldrich) was injected intraperitoneally (i.p.) at 50 μg per kg of body weight at the indicated times. For neutralization and depletion studies, anti-mouse IFN-γ (1 mg, clone XMG1.2, Bio X Cell), anti-mouse CD11c (500 μg, clone N418, Bio X Cell), anti-mouse CD8 (250 μg, clone 53-6.72, Bio X Cell), anti-mouse CD4 (150 μg, clone GK1.5, Bio X Cell), or anti-mouse CD25 (500 μg, clone PC-61.5.3, Bio X Cell) was injected i.p. at the indicated times. Isotype control antibodies used were rat IgG1, Armenian hamster IgG, or rat IgG2a from Bio X Cell, respectively.
9
In vivo neutralization of IL-1α and IL-1β
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For in vivo neutralization of IL-1α and IL-1β, C57BL/6J WT mice were i.v. injected with 250 μg of anti-IL-1α (clone ALF-161; BioXCell), anti-IL-1β (clone B122; BioXCell), or an IgG isotype control (Armenian hamster IgG; BioXCell) Ab 24 h before the induction of mild rickettsiosis using 105 PFU of R. typhi , R. rickettsii , or R. montanensis .
10
Immunomodulatory Therapy for Melanoma
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!